Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AVT29

Other · developed by Alvotech Swiss

Phase 3 Most advanced trial

ALVO Developer

1 Registered trials

What is AVT29?

AVT29 is an agent given by intravitreal (IVT) injection. It is studied in diabetic macular edema, an eye disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Ophthalmology
Developer: Alvotech Swiss AG (ALVO)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07489131	Phase 3	Diabetic Macular Edema	Recruiting	ALVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetic Macular Edema

More from Alvotech Swiss

AVT03 Phase 3 AVT04 Phase 3 AVT05 Phase 3 AVT06 Phase 3 AVT16 Phase 3 AVT32-DRL_PB Phase 1 AVT80 Phase 1

Sources

ClinicalTrials.gov NCT07489131

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALVO page.

Follow ALVO, the company behind AVT29

See ALVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALVO catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z